|
Amyloidosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we define the following intracellular mechanisms regulated by 1,25D3 that are associated with recovery of phagocytosis and consistent with the selectivity of BDC: 1) 1,25D3 potentiates a 4,4-diisothiocyanostilbene-2,2-disulfonic acid-sensitive chloride channel (i.e., ClC-3) currents in both Type I and II AD macrophages, but curcumin only potentiates the currents in Type I cells; 2) 1,25D3 is particularly effective in upregulating ClC-3 mRNA expression in Type II peripheral blood mononuclear cells (PBMCs) while both 1,25D3 and the BDC analog, C180, upregulate VDR mRNA, repressed by Aβ42 in Type II PBMCs; and 3) 1,25D3-induced Aβ42 phagocytosis is attenuated by the calcium-dependent ClC-3 blocker, inositol 3,4,5,6-tetraphosphate (IP4), in both AD Types and by the MEK1/2 inhibitor U0126 only in Type II macrophages.
|
22207005 |
2012 |
|
Cardiovascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The ClC-3 chloride channels in cardiovascular disease.
|
21602838 |
2011 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure.
|
21602838 |
2011 |
|
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure.
|
21602838 |
2011 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
This review will highlight the major findings and recent advances in the study of ClC-3 Cl(-) channels in the cardiovascular system and discuss their important roles in cardiac and vascular remodeling during hypertension, myocardial hypertrophy, ischemia/reperfusion, and heart failure.
|
21602838 |
2011 |
|
Nasal Polyps
|
0.010 |
AlteredExpression
|
disease |
LHGDN |
TGF-beta and IL-4 may modulate the expression of CLC-2 and CLC-3 in CRSsNP.
|
17882904 |
2007 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2-dependent modulation of swelling-activated Cl- current and ClC-3 expression in human prostate cancer epithelial cells.
|
15256454 |
2004 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Bcl-2-dependent modulation of swelling-activated Cl- current and ClC-3 expression in human prostate cancer epithelial cells.
|
15256454 |
2004 |
|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
In this study, we have shown that heterologous expression of ClC-3 in either Chinese hamster ovary (CHO-K1) or human hepatoma (Huh-7) cells results in the formation of large, acidic vesicular structures within cells.
|
11997263 |
2002 |
|
Developmental delay (disorder)
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion.
|
12059962 |
2002 |
|
Blindness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion.
|
12059962 |
2002 |
|
Global developmental delay
|
0.010 |
Biomarker
|
disease |
BEFREE |
Together with developmental retardation and higher mortality, the Clcn3-/- mice showed neurological manifestations such as blindness, motor coordination deficit, and spontaneous hyperlocomotion.
|
12059962 |
2002 |
|
Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A total of 14 clones could be matched to known genes and were categorized into four groups: A) transcription factors: prothymosin, CA150, p78 serine/threonine kinase, IL-1beta-stimulating gene, glucocorticoid receptor, MLN64/CAB1, gastrin-binding protein, and polypeptide from glioblastoma; B) chaperone: 90 kDa heat shock protein; C) ion channel: chloride channel protein 3; and D) cytoskeleton: cytovillin2/ezrin and vimentin.
|
11146166 |
2000 |
|
Adult Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A total of 14 clones could be matched to known genes and were categorized into four groups: A) transcription factors: prothymosin, CA150, p78 serine/threonine kinase, IL-1beta-stimulating gene, glucocorticoid receptor, MLN64/CAB1, gastrin-binding protein, and polypeptide from glioblastoma; B) chaperone: 90 kDa heat shock protein; C) ion channel: chloride channel protein 3; and D) cytoskeleton: cytovillin2/ezrin and vimentin.
|
11146166 |
2000 |
|
Childhood Glioblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A total of 14 clones could be matched to known genes and were categorized into four groups: A) transcription factors: prothymosin, CA150, p78 serine/threonine kinase, IL-1beta-stimulating gene, glucocorticoid receptor, MLN64/CAB1, gastrin-binding protein, and polypeptide from glioblastoma; B) chaperone: 90 kDa heat shock protein; C) ion channel: chloride channel protein 3; and D) cytoskeleton: cytovillin2/ezrin and vimentin.
|
11146166 |
2000 |
|
Glioblastoma Multiforme
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A total of 14 clones could be matched to known genes and were categorized into four groups: A) transcription factors: prothymosin, CA150, p78 serine/threonine kinase, IL-1beta-stimulating gene, glucocorticoid receptor, MLN64/CAB1, gastrin-binding protein, and polypeptide from glioblastoma; B) chaperone: 90 kDa heat shock protein; C) ion channel: chloride channel protein 3; and D) cytoskeleton: cytovillin2/ezrin and vimentin.
|
11146166 |
2000 |
|
Chorea
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Considering that chorea in this patient might be due to the disruption of a gene at either of the 4p15.32 or 4q33 breakpoints, CLCN3 was considered as a candidate gene.
|
9521585 |
1998 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
ClC-3 may be an important promoter for aggressive metastasis of malignant tumors.
|
30636929 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Chloride channel 3 (CIC-3) has been suggested to be implicated in the carcinogenesis though; it still remains ill understood in hepatocarcinoma, especially in terms of clinicopathological meaning of its expression.
|
30678806 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
ClC-3 is a type of chloride channel that has multiple functions in tumorigenesis and tumor growth, and can be blocked by DIDS (4,4'-diisothiocyanostilbene-2,2'-disulfonic acid).
|
29749557 |
2018 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The molecular mechanisms by which CLC-3 is regulated in GC are unclear.
|
30217218 |
2018 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings indicate the vital role of CLC-3 in gastric cancer progression and its potential role of a therapeutic target for treatment.
|
29795988 |
2018 |
|
Vascular inflammations
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our previous study found that ClC-3 chloride channel functioned differently in the vascular and intestinal inflammation, the loss of ClC-3 reduced vascular inflammation but exacerbated intestinal inflammation.
|
29972266 |
2018 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Therefore, cytoplasmic ClC-3 plays an active and key role in tumor metastasis and may be a valuable prognostic biomarker and a therapeutic target to prevent tumor spread.
|
25537517 |
2015 |
|
Vascular inflammations
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, TNFα-induced vascular inflammation and neutrophil infiltration into the lung and liver were obviously attenuated in ClC-3 knockout mice (P<0.01; n=7).
|
23006728 |
2012 |